Microbix Partners with ACPCC to Combat Cervical Cancer in Indo-Pacific

The latest announcement is out from Microbix Biosystms ( (TSE:MBX) ).

Microbix Biosystems Inc. has signed a Memorandum of Understanding with the Australian Centre for the Prevention of Cervical Cancer (ACPCC) to supply its PROCEEDxFLOQ brand Quality Assessment Products (QAPs) to support the accuracy of HPV testing in the Indo-Pacific region. This collaboration is part of the EPICC program, which aims to eliminate cervical cancer in the region by improving the prevention, diagnosis, and treatment of the disease. The initiative is supported by the Australian Government and philanthropic partners and seeks to extend its proven model to additional countries, enhancing access to accurate HPV testing and reducing the human toll of cervical cancer.

More about Microbix Biosystms

Microbix Biosystems Inc. is a life sciences company that creates proprietary biological products for human health. With over 120 skilled employees, it focuses on manufacturing and exporting critical ingredients and devices for the global diagnostics industry. Notably, it produces antigens for immunoassays and laboratory quality assessment products (QAPs) that support clinical lab proficiency testing and ensure the quality of clinical diagnostic workflows. Microbix products are available in over 30 countries, supported by a network of international distributors, and the company is accredited by several international health organizations.

YTD Price Performance: -6.17%

Average Trading Volume: 205,224

Technical Sentiment Consensus Rating: Hold

Current Market Cap: C$54.08M

For an in-depth examination of MBX stock, go to TipRanks’ Stock Analysis page.